FDA Approves GSK’s Hibsago, the First Antisense Drug for Chronic Hepatitis B
The US FDA has approved GSK’s Hibsago (bepirovirsen), a six-month injectable course that left about one in five patients with a "functional cure" of chronic hepatitis B in trials, compared with none on placebo.